08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors

04/07/2025 – AB Science today announced that a confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer has been authorized by FDA and EMA, with a biomarker that targets patients with less advanced metastatic disease

30/06/2025 – AB Science today announced that an agreement in principle has been reached with its financial creditors to postpone by 24 months the repayment of its bank debt

23/06/2025 – AB Science today announced that a new study from an independent research team based in China presents new evidences showing that masitinib offers a promising new approach to treating Alzheimer’s disease

12/06/2025 – AB Science today announced that the patent office of Canada has  granted a patent protecting the composition of matter of AB8939, and closely related compounds, until 2036

09/06/2025 – AB Science today announced that the European Medicine Agency (EMA) has approved the extension of the shelf life of its veterinary medicine MASIVET® from 36 months to 48 months